by Dr. Ed Weber | May 10, 2023 | PCa Commentary
Decipher assays the RNA expression of 22 genes and estimates the rate of distant metastases at 5 years and prostate cancer-specific mortality at 10 years, thus providing risk stratification to assist in treatment decisions. Three examples: providing guidance for men...
by Dr. Ed Weber | May 4, 2023 | PCa Commentary
But First, the Biology of Inhibition of PARP (Poly (ADP-Ribose) Polymerase): Briefly. In the myriad of cell divisions random mistakes are made in the faithful transcription of DNA into daughter cells. Some errors are of no consequence (passenger mutations),...
by Dr. Ed Weber | Mar 30, 2023 | PCa Commentary
Treatment regimens for mHSPC have been multiply meta-analyzed, likely because of its increasing occurrence. “mHSPC” refers to metastatic cancer imaged at initial diagnosis prior to primary therapy. The higher incidence may be due to the decrease in PSA testing...
by Dr. Ed Weber | Mar 29, 2023 | PCa Commentary
Bipolar Androgen Therapy (BAT) has been validated as an effective, but likely underused, option in the sequence of treatments for metastatic castration-resistant prostate cancer (mCRPC). What is BAT and Where Does It Fit In? BAT is the monthly cyclic elevation of...
by Dr. Ed Weber | Feb 14, 2023 | PCa Commentary
The set-point for biochemical failure was standardized in 2006 based on a consensus conference of experts in Phoenix, Arizona. The value agreed upon was “PSA + 2 ng/mL above the post-radiation PSA nadir — hence the “Phoenix Definition.” (Roach et...
